RNR BioMedical

RNR BioMedical is a South Korean biotechnology company focused on the development of novel anti-cancer therapeutics targeting ribonucleotide reductase (RNR). RNR is a rate-limiting enzyme essential for DNA synthesis and repair, making it a high-value target in oncology. The company aims to develop small molecule inhibitors that offer superior potency and safety compared to traditional RNR inhibitors like hydroxyurea. Their lead candidate, RNR-001, is being advanced for the treatment of various solid tumors and blood cancers. RNR BioMedical's approach combines structural biology and medicinal chemistry to address unmet needs in the oncology space. The company was founded as a spin-off from research conducted at the Asan Medical Center.